1 / 24

Typical Pre-Clinical Steps in Development

FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine. Typical Pre-Clinical Steps in Development. Elements of Clinical Trial Design in IBD. Patient Selection Intervention Outcomes.

harding-fry
Download Presentation

Typical Pre-Clinical Steps in Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease?Alan C. Moss MD, FEBG, FACG, AGAFAssociate Professor of Medicine

  2. Typical Pre-Clinical Steps in Development

  3. Elements of Clinical Trial Design in IBD • Patient Selection • Intervention • Outcomes

  4. Patient Selection

  5. Populations in Prior FMT Trials in IBD

  6. “Ideal” Populations to Study • Early after diagnosis, prior to immunosuppresive therapy • Early after Crohn’s resection to prevent endoscopic recurrence • Genotype-specific • Patients in remission to reduce risk of relapse • Proctitis (UC) – mode of administration • Pouchitis (UC) • Active ileal Crohn’s - ?more dysbiosis driven

  7. 100 90 80 70 60 Penetrating 50 Cumulative Probability (%) Inflammatory 40 30 Stricturing 20 10 0 0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 204 216 228 240 Months Rationale for Earlier Intervention - Window of Inflammation Cosnes J, et al. Inflamm Bowel Dis. 2002;8:244-250.

  8. Rational for Early Intervention - Dysbiosis is Established Early Gevers D et al Cell Host Microbe. 2014 Mar 12;15(3):382-92

  9. Rationale for Genotype Enrichment Frank DN, Inflamm Bowel Dis. 2011 Jan;17(1):179-84

  10. Who to Exclude • Food allergies • Pregnant • Cancer • Immunocompromised • Cirrhosis • History of valvular heart disease

  11. Variables to Control for in Enrolled Population Sommer F, Nat Rev Microbiol. 2013 Apr;11(4):227-38

  12. Interventions

  13. Variables to Consider for Intervention 1. Dose 2. Delivery 3. Duration • Stool weight • Solution concentration • Microbial consituents • Aerobe / Anerobic prep • Naso-jejnual • Enema • Colonoscopy • Capsule • Fresh / Frozen • Loading & Maintenance • Frequency of administration

  14. Scenarios for Intervention – Parallel Design 100g Freeze-Thaw FMT 50g Freeze-Thaw FMT Study Population Randomize Sham FMT 100g Fresh FMT 100g Freeze-Thaw FMT Study Population Randomize Probiotics

  15. Scenarios for Intervention – Cross-Over Sham FMT 100g Freeze-Thaw FMT Randomize Sham FMT 100g Freeze-Thaw FMT

  16. Solutions to Uncertainties in Intervention • Tailor administration to site of inflammation • Standard concentration (fecal slurry by donor weight and re-constitution solution) • Frozen pre-screened aliquots • Regular administration - colonization alone does not guarantee efficacy

  17. Frozen Donor Stool Retains its Diversity Carroll I, PLoS One. 2012; 7(10): e46953

  18. Single FMT Not Sufficient – Data in Crohn’s R1001 20 R1002 R1003 15 R1004 I R1005 B H 10 R1006 R1007 R1008 5 R1009 R101 1 0 e 1 2 4 8 T 2 4 n 1 2 M k k k k R1012 i l e e e e k k F e e e e e e e s e e a W W W W W W B Vaughn B, DDW 2014

  19. Outcomes

  20. Clinical Efficacy Outcomes • Measure of Response / Remission - endoscopic measure important - Patient Reported Outcomes (PROs) - CDAI, SCCAI no longer convincing alone - Quality of Life • Timing of Outcome Assessment - 4 & 8 weeks for response - week 8 and 26 for remission (endoscopic)

  21. Safety • Reporting of Adverse Events has been inadequate to date • Use of industry-standards for attribution and severity important • Long-term surveillance critical (storage of archival donor samples for testing)

  22. Physiological Outcomes • Paired diversity assessments (pre- & post-) • Metabolomics • Inflammatory markers – CRP, Fecal Calprotectin • T-cell phenotypes

  23. FMT Clinical / Safety Assessment LP T-cell phenotypes PB T-cell phenotypes Microbiome Sequencing 4 8 Weeks 0 12 24 “Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients Inflammatory Bowel Disease” ClinicalTrials.gov Identifier:NCT01847170

  24. Conclusions • FMT should be studied in similar manner to drug therapy to test its efficacy & safety - risk:benefit, cost-effectiveness • Challenges – regulatory, funding, standardization • Initial promise tempered by variable open-label study outcomes • Need for tailored intervention in targeted sub-groups of patients with IBD

More Related